TIL · Instil Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $669.0K | - | $9.13M | $6.74M | $7.26M | - | $562.0K | $2.92M | $7.26M | - |
| SG&A | $5.35M | - | $5.89M | $6.16M | $9.11M | - | $10.71M | $10.71M | $12.42M | - |
| Total Operating Expenses | $7.01M | - | $15.02M | $23.44M | $30.56M | - | $23.63M | $14.13M | $23.95M | - |
| D&A | $12.0K | - | $10.0K | $0 | $498.0K | - | $900.0K | $1.00M | $993.0K | - |
| Operating Income | ($7.01M) | - | ($15.02M) | ($23.44M) | ($30.56M) | - | ($23.63M) | ($14.13M) | ($23.95M) | - |
| Interest Expense | $1.55M | - | $1.58M | $1.58M | $1.98M | - | $2.01M | $590.0K | $1.98M | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($4.20M) | - | ($13.59M) | ($21.39M) | ($28.20M) | - | ($23.02M) | ($14.92M) | ($24.30M) | - |
| EPS - Basic | ($0.62) | - | ($2.01) | ($3.24) | ($4.32) | - | ($3.54) | ($2.29) | ($3.74) | - |
| EPS - Diluted | ($0.62) | - | ($2.01) | ($3.24) | ($4.32) | - | ($3.54) | ($2.29) | ($3.74) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.02M | $6.64M | $5.80M | $7.69M | $15.37M | $8.80M | $6.66M | $6.78M | $5.48M | $9.20M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $793.0K | $779.0K | $928.0K | $523.0K | $286.0K | $659.0K | $1.20M | $1.22M | $1.23M | $1.21M |
| Current Assets | $188.30M | $191.43M | $196.26M | $207.39M | $219.26M | $124.47M | $132.57M | $154.93M | $161.03M | $160.76M |
| Total Assets | $200.43M | $203.52M | $211.77M | $230.99M | $237.45M | $263.57M | $272.56M | $294.32M | $306.30M | $325.63M |
| Current Liabilities | $4.72M | $4.84M | $5.70M | $13.85M | $7.23M | $7.90M | $10.28M | $10.29M | $11.35M | $10.56M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $89.73M | $89.66M | $91.35M | $99.32M | $92.54M | $94.13M | $96.23M | $99.30M | $100.48M | $99.80M |
| Stockholders' Equity | $110.70M | $113.87M | $120.42M | $131.67M | $144.91M | $169.44M | $176.33M | $195.02M | $205.83M | $225.83M |
| Retained Earnings | ($730.69M) | ($726.49M) | ($718.30M) | ($704.71M) | ($683.32M) | ($655.12M) | ($643.22M) | ($620.20M) | ($605.28M) | ($580.98M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.34M) | - | - | - | ($4.20M) | - | - | - | ($14.39M) | - |
| Investing Cash Flow | ($317.0K) | - | - | - | $9.61M | - | - | - | $9.24M | - |
| Financing Cash Flow | $0 | - | - | - | $232.0K | - | - | - | $0 | - |
| CapEx | - | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($14.39M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.59 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -2.1% | - | -6.4% | -9.3% | -11.9% | - | -8.4% | -5.1% | -7.9% | - |
| Return on equity | -3.8% | - | -11.3% | -16.2% | -19.5% | - | -13.1% | -7.6% | -11.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 39.87 | 39.53 | 34.45 | 14.97 | 30.33 | 15.76 | 12.90 | 15.06 | 14.19 | 15.22 |
| Quick ratio | 39.87 | 39.53 | 34.45 | 14.97 | 30.33 | 15.76 | 12.90 | 15.06 | 14.19 | 15.22 |
| Cash ratio | 1.06 | 1.37 | 1.02 | 0.56 | 2.13 | 1.12 | 0.65 | 0.66 | 0.48 | 0.87 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -4.5x | - | -9.5x | -14.8x | -15.4x | - | -11.8x | -24.0x | -12.1x | - |
| Equity multiplier | 1.81 | 1.79 | 1.76 | 1.75 | 1.64 | 1.56 | 1.55 | 1.51 | 1.49 | 1.44 |
| Liabilities / Assets | 0.45 | 0.44 | 0.43 | 0.43 | 0.39 | 0.36 | 0.35 | 0.34 | 0.33 | 0.31 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.5x | - | 1.0x | 1.0x | 0.8x | - | 2.5x | 0.3x | 0.3x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 77.1% | - | 36.4% | -65.8% | -27.6% | - | 64.6% | 32.6% | 59.0% | - |
| Net income growth (YoY) | 85.1% | - | 41.0% | -43.4% | -16.0% | - | 65.9% | 20.1% | 57.4% | - |
| EPS growth (YoY) | 85.6% | - | 43.2% | -41.5% | -15.5% | - | -580.8% | -1535.7% | -750.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 66.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -23.6% | -32.8% | -31.7% | -32.5% | -29.6% | -25.0% | -24.7% | -34.2% | -33.9% | -37.9% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Instil Bio against the 5 most active filers in the same SIC group.